Comparing FluoroPharma Medical (OTCMKTS:FPMI) & ICU Medical (NASDAQ:ICUI)

FluoroPharma Medical (OTCMKTS:FPMI) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Institutional & Insider Ownership

96.1% of ICU Medical shares are owned by institutional investors. 36.9% of FluoroPharma Medical shares are owned by company insiders. Comparatively, 2.1% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares FluoroPharma Medical and ICU Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A
ICU Medical	$2.23 billion	1.49	$730,000.00	$1.85	72.06

ICU Medical has higher revenue and earnings than FluoroPharma Medical.

Analyst Ratings

This is a summary of current ratings and target prices for FluoroPharma Medical and ICU Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FluoroPharma Medical	0	0	0	0	0.00
ICU Medical	1	0	2	2	3.00

ICU Medical has a consensus price target of $169.00, indicating a potential upside of 26.77%. Given ICU Medical’s stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than FluoroPharma Medical.

Risk and Volatility

FluoroPharma Medical has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Profitability

This table compares FluoroPharma Medical and ICU Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FluoroPharma Medical	N/A	N/A	N/A
ICU Medical	2.15%	7.50%	3.91%

Summary

ICU Medical beats FluoroPharma Medical on 10 of the 11 factors compared between the two stocks.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.